DNAPrint Genomics, Inc. Adds Ramin Mirhashemi, M.D. to Scientific Advisory Board
Business Editors/Health & Medical Writers
SARASOTA, Fla.--(BUSINESS WIRE)--Sept. 27, 2000--DNAPrint genomics, Inc., (Pink Sheets:DNAP), a Sarasota, Florida based genomics company, announced today that has added Ramin Mirhashemi, M.D. to its Scientific Advisory Board. Dr. Mirhashemi, currently serves as Director of the University of Miami/JMH/Sylvester Cancer Center and Familial Ovarian/Breast Cancer Center, in Miami, Florida. He is an assistant Professor, Department of Obstetrics and Gynecology and a Clinical Fellow in Gynecologic Oncology at the University of Miami School of Medicine. Dr. Mirhashemi is the recipient of the prestigious ACOG/Ortho-McNeil Fellowship Grant, and has accumulated 8 different honors and awards as a Gynecologic Oncologist and Surgeon.
CEO/CSO Dr. Tony Frudakis said, "Dr. Mirhashemi is an extremely valuable addition to our Scientific Advisory Board. His experience and expertise with biopharmaceutical partners and experimental/clinical trial study design will help guide the structure and placement of our cancer pharmacogenomics studies."
About DNAPrint genomics
DNAPrint genomics, Inc. is developing complex genetic analytics and knowledge resources for next generations personalized medicine. The company provides practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. For more information about the company, please visit www.dnaprint.com.
Except for factual statements made herein, the information contained in this press release consists of forward-looking statements that involve risks and uncertainties. The Company's actual results could differ materially from those contained in such statements. Factors that could cause or contribute to such differences include unexpected shortages of critical components, rescheduling or cancellation of customer orders, the timing and market acceptance of new product introductions by the Company and its competitors, and general competition and price pressures in the marketplace.
--30--law/mi*
CONTACT: DNAPrint Genomics, Inc., Sarasota
Scientific Inquiries:
Tony Frudakis, 941/351-4543
or
All Other Inquiries:
Richard Craig Hall, 941/341-0136 |
